|
|
|
16.01.26 - 11:36
|
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal (PBR)
|
|
|
The collaboration secures funding and sustained biologics manufacturing capacity in the US for Agenus, supporting clinical development, early access initiatives, and future commercial production. Under the agreement, Agenus
The post Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
|
|
18.11.25 - 14:42
|
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France′s AAC (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOTBAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel (AAC) program.
BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has historically derived limited benefit from immunotherapy despite substantial unmet medical need.
Dr. Iglesias brings over 30 years of global oncology and immuno-oncology drug development experience. Previously, at Abraxis BioScience and Celgene, he led late-stage develop...
|
|
|
|
|
|
|
10.11.25 - 13:36
|
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances (Business Wire)
|
|
|
France grants reimbursed access with patients having commenced treatment
Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients
Phase 3 on track to commence in fourth quarter 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOT--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial.
Access & Regulatory
France authorizes reimbursed AAC for BOT/BAL. In September, France's medicines agency (ANSM) authorized reimbursed compassionate access (Accès Compassionnel, AAC) for BOT/BAL in refractory MSS mCRC without active liver metastases—the first government-funded access for this population ...
|
|
|
|
|
|
|
05.11.25 - 19:48
|
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--$AGEN #BOTBAL--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025.
The company also plans to host a stakeholder briefing webcast in late November to provide a corporate and clinical development update. Additional details regarding the webcast will be announced in the coming weeks.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and ...
|
|
|
|
|
|
|
|
|
11.08.25 - 13:33
|
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress (Business Wire)
|
|
|
Zydus Lifesciences collaboration to close in Q3 with $91M capital infusion to support clinical and regulatory milestones
BOT/BAL delivers 42% two-year survival in refractory MSS CRC and consistent activity across multiple solid cancers, to be presented at an oral session at ESMO
Regulatory alignment secured for Phase 3 trial initiation, expected to commence in Q4 2025
August 27th virtual stakeholder meeting set for a detailed discussion on progress
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today reports financial results for the second quarter of 2025 and highlighted major clinical, regulatory, and operational milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) immunotherapy combination. Botensilimab is a next-generation, multifunctional, Fc enhanced, CTLA-4 antibody and BAL is a proprietary PD-1 antibody; together they are designed to trigger robust and durable immu...
|
|
|
|
|
31.07.25 - 13:36
|
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report (Business Wire)
|
|
|
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2025 financial results before the market opens on Monday, August 11, 2025. Agenus will then host a stakeholder briefing in late August to spotlight key strategic plans, data milestones and provide a comprehensive update on the global botensilimab (BOT) and balstilimab (BAL) development program.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery,...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
